• AXA IM
  • Gene editing: The biotech bringing potential new investment opportunities
Investment Institute
Macroeconomic Research

Gene editing: The biotech bringing potential new investment opportunities

  • 24 February 2021 (5 min read)

The coronavirus pandemic has made biotechnology front page news. The arrival of multiple vaccines in record time has starkly highlighted how innovative – and versatile – the sector can be.

Its new position under the spotlight injected a healthy dose of momentum into what can at times be a volatile market and certainly investors have understandably been honing in on the biotech and pharmaceutical industries. In 2020 the NASDAQ Biotechnology Index delivered a 26% total return while the S&P Biotechnology Index achieved 48%, versus 18% from the wider S&P 500.1

While the present focus is rightly on inoculating the global population against coronavirus, simultaneously there is a myriad of other work taking place, not least in the gene-editing space. A world away from the typical media portrayal of genetically modified ‘Frankenstein foods’ and ‘designer babies’, gene editing is a cutting-edge technique transforming scientific research, food production and ultimately how we can tackle life-threatening illnesses.

What is gene editing?

DNA is the blueprint of everything that makes us, us. It consists of 3.2 billion bases linked together into long chains arranged in a slightly different order from person to person. Gene or genome editing is a type of genetic engineering where DNA is deleted, inserted, replaced or altered in the genome of a living organism.

The unique sequence is ordered into genes, some of which direct the body to make proteins. The Human Genome project, an international effort, sequenced the first full human genome in 2003.2

The completion of the project arguably marked the start of a new era of medical innovation in which scientists could investigate and comprehend the underlying genetic causes of disease. Rapid improvements in technology drove down the time and cost of sequencing - the first human genome took 13 years and cost $2.7bn. Today the equivalent of an entire genome is sequenced every second and can be done so for less than $1,000.3

Where are we now?

All this genetic data is rapidly improving our understanding of diseases because “all diseases have a genetic component”.4

While many diseases are complex, involving contributions from multiple genes and environmental stimuli, there are approximately 5,000 to 8,000 diseases caused by a single genetic mutation. This fact creates an opportunity to apply a novel technology, gene editing, with potentially curative results.5

There are several firms working in this field but perhaps the best-known gene editing tool is CRISPR/Cas-9. The scientists behind the discovery - Emmanuelle Charpentier and Jennifer A. Doudna - received the Nobel Prize in Chemistry last year.6

The tool can cut DNA in specific places with high precision. The technology is composed of two main parts; a targeting molecule known as a ‘guide’, and a cutting tool, or ‘endonuclease’ that cuts the DNA at the specific sequence.

Essentially it can help turn off a faulty gene or prevent suppression of another gene or create a space into which other genetic material can be added.

Track record

These tools are already being tested in clinical trials and showing life-changing and, potentially, curative results for two rare blood disorders, beta thalassemia and sickle cell disease - both of which prevent the production of normal haemoglobin, the protein that carries oxygen in our blood.

These are life-long illnesses for which there is currently no cure. But an ongoing clinical trial, funded by biotech company CRISPR Therapeutics in partnership with Vertex, is showing remarkable early results and providing reasons to believe a cure for these diseases may ultimately be achievable utilising novel technologies such as gene editing. In many serious cases of beta thalassemia, patients require regular blood transfusions to prevent anaemia.  Patients who enrolled in the trial required on average 15 transfusions per year before treatment, and six months post-treatment all patients were transfusion free. The trial is ongoing and new patient data is still emerging7 .

This is just one example of the applications of gene editing - already efforts are underway to apply this novel technology to range of diseases affecting different parts of the human anatomy. For example, Editas Medicine is working on correcting gene mutations that cause rare causes of blindness and Beam Therapeutics is harnessing gene editing to treat protein deficiency disorders, and produce immune cells capable of better targeting cancer cells.

The long-term potential

Gene editing is already being used widely in scientific research to accelerate new discoveries - and it has the potential to revolutionise medicine. The technology has been known for decades, but we are still very much in the infancy of investigating its use in human disease.

  • UyZhbXA7UCBCaW90ZWNoIEluZGV4IC8gTkFTREFRIEJpb3RlY2hub2xvZ3kgSW5kZXggLyBGYWN0c2V0IERhdGEgKGFzIGF0IDMxIERlY2VtYmVyLCAyMDIwKQ==
  • TmF0aW9uYWwgSHVtYW4gR2Vub21lIFJlc2VhcmNoIEluc3RpdHV0ZQ==
  • RE5BIHNlcXVlbmNpbmcgdGFja2xlcyBnbG9iYWwgY2hhbGxlbmdlcyAodWtyaS5vcmcp
  • aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9ib29rcy9OQksxMzIxNDIv
  • Um9kd2VsbCwgQy4sIEF5bcOpLCBTLiAoZWRzLikgKDIwMTQpLiAyMDE0IFJlcG9ydCBvbiB0aGUgU3RhdGUgb2YgdGhlIEFydCBvZiBSYXJlIERpc2Vhc2UgQWN0aXZpdGllcyBpbiBFdXJvcGUgUGFydCBJaTogS2V5IERldmVsb3BtZW50cyBpbiB0aGUgRmllbGQgb2YgUmFyZSBEaXNlYXNlcyBpbiBFdXJvcGUgaW4gMjAxMy4gMeKAkzkw
  • aHR0cHM6Ly93d3cubm9iZWxwcml6ZS5vcmcvcHJpemVzL2NoZW1pc3RyeS8yMDIwL3ByZXNzLXJlbGVhc2Uv
  • aHR0cHM6Ly9jcmlzcHJ0eC5nY3Mtd2ViLmNvbS8=

    Not for Retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    This promotional communication does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee that forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice.

    The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    Disclaimer

    This website is published by AXA Investment Managers Asia Limited (“AXA IM HK”), an entity licensed by the Securities and Futures Commission of Hong Kong (“SFC”), for general circulation and informational purposes only. It does not constitute investment research or financial analysis relating to transactions in financial instruments, nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy, sell or enter into any transactions in respect of any investments, products or services, and should not be considered as solicitation or investment, legal, tax or any other advice, a recommendation for an investment strategy or a personalised recommendation to buy or sell securities under any applicable law or regulation. It has been prepared without taking into account the specific personal circumstances, investment objectives, financial situation, investment knowledge or particular needs of any particular person and may be subject to change at any time without notice. Offering may be made only on the basis of the information disclosed in the relevant offering documents. Please consult independent financial or other professional advisers if you are unsure about any information contained herein.

    Due to its simplification, this publication is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee such opinions, estimates and forecasts made will come to pass. Actual results of operations and achievements may differ materially. Data, figures, declarations, analysis, predictions and other information in this publication is provided based on our state of knowledge at the time of creation of this publication. Information herein may be obtained from sources believed to be reliable. AXA IM HK has reasonable belief that such information is accurate, complete and up-to-date. To the maximum extent permitted by law, AXA IM HK, its affiliates, directors, officers or employees take no responsibility for the data provided by third party, including the accuracy of such data. This material does not contain sufficient information to support an investment decision. References to companies (if any) are for illustrative purposes only and should not be viewed as investment recommendations or solicitations.

    All investment involves risk, including the loss of capital. The value of investments and the income from them can fluctuate and that past performance is no guarantee of future returns, investors may not get back the amount originally invested. Investors should not make any investment decision based on this material alone. 

    Some of the services listed on this Website may not be available for offer to retail investors.

    This Website has not been reviewed by the SFC. © 2022 AXA Investment Managers. All rights reserved.